Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
International Journal of Clinical Oncology
Published in: International Journal of Clinical Oncology 1/2013

01-02-2013 | Original Article

Caffeine-potentiated chemotherapy for clear cell sarcoma: a report of five cases

Authors: Michiaki Karita, Hiroyuki Tsuchiya, Norio Yamamoto, Toshiharu Shirai, Katsuhiro Hayashi, Hideji Nishida

Published in: International Journal of Clinical Oncology | Issue 1/2013

Login to get access

Abstract

Background

Clear cell sarcoma is a rare malignant tumor of soft tissue which is most commonly encountered in the extremities, especially in the foot and ankle. This tumor is slow-growing and looks like a benign tumor; it is therefore often treated inadequately and its high rate of recurrence and metastases results in a poor prognosis. Caffeine has been used as a chemotherapy potentiator that inhibits DNA damage repair and enhances the cytocidal effects of anti-cancer drugs. This study reports the effect of caffeine-potentiated chemotherapy for clear cell sarcoma in five patients.

Methods

Caffeine-potentiated chemotherapy was administered to five patients with clear cell sarcoma. Three to five courses of intra-arterial chemotherapy using cisplatin, doxorubicin and caffeine were administered preoperatively, at 3-week intervals. Conservatively, wide margin surgery was performed following the preoperative chemotherapy. Intravenous cisplatin and doxorubicin with caffeine were administered three to six times to the patients who responded to the preoperative chemotherapy. This study evaluated the response to chemotherapy, recurrence, metastasis and the overall prognosis in these five patients.

Results

Four of the eligible patients responded to preoperative chemotherapy. Local recurrence occurred in only one of the five patients. Distant metastasis newly developed in one patient. All five patients survive.

Conclusion

Caffeine-potentiated chemotherapy can be effective treatment for clear cell sarcoma not only as initial therapy, but also as salvage therapy.
Literature
1.
Enzinger FM, Weiss SW, Goldblum JR (2001) Soft tissue tumors, 4th edn. Mosby, St. Louis, pp 1241–1250
2.
Enzinger FM (1965) Clear cell sarcoma of tendons and aponeuroses. An analysis of 21 cases. Cancer 18:1163–1174PubMedCrossRef
3.
Tsuneyoshi M, Enjoji M, Kubo T (1978) Clear cell sarcoma of tendons and aponeuroses. A comparative study of 13 cases with provisional subgrouping into the melanotic and synovial types. Cancer 42:243–252PubMedCrossRef
4.
Langezaal SM, Graadt van Roggen JF, Cleton-Jansen AM et al (2001) Malignant melanoma is genetically distinct from clear cell sarcoma of tendons and aponeurosis (malignant melanoma of soft parts). Br J Cancer 84:535–538PubMedCrossRef
5.
Zucman J, Delattre O, Desmaze C et al (1993) EWS and ATF-1 gene fusion induced by t(12;22) translocation in malignant melanoma of soft parts. Nat Genet 4:341–345PubMedCrossRef
6.
Pavlidis NA, Fisher C, Wiltshaw E (1984) Clear-cell sarcoma of tendons and aponeuroses: a clinicopathologic study. Presentation of six additional cases with review of the literature. Cancer 54:1412–1417PubMedCrossRef
7.
Enneking WF (1986) A system of staging musculoskeletal neoplasms. Clin Orthop 204:9–24PubMed
8.
Tsuchiya H, Tomita K, Mori Y et al (1998) Caffeine-assisted chemotherapy and minimized tumor excision for nonmetastatic osteosarcoma. Anticancer Res 18:657–666PubMed
9.
Tsuchiya H, Tomita K, Yamamoto N et al (1998) Caffeine-potentiated chemotherapy and conservative surgery for high-grade soft tissue sarcomas. Anticancer Res 18:3651–3656PubMed
10.
Tsuchiya H, Tomita K, Mori Y et al (1999) Marginal excision for osteosarcoma with caffeine assisted chemotherapy. Clin Orthop 358:27–35PubMed
11.
Therasse P, Arbuck SG, Eisenhauer EA (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216PubMedCrossRef
12.
Jacobs IA, Chang CK, Guzman G et al (2004) Clear cell sarcoma: an institutional review. Am Surg 70:300–303PubMed
13.
Kuiper DR, Hoekstra HJ, Veth RPH et al (2003) The management of clear cell sarcoma. EJSO 29:568–570PubMedCrossRef
14.
Ferrari A, Casanova M, Bisogno G et al (2002) Clear cell sarcoma of tendons and aponeuroses in pediatric patients: a report from the Italian and German soft tissue sarcoma cooperative group. Cancer 94:3269–3276PubMedCrossRef
15.
Finley JW, Hanypsiak B, McGrath B et al (2001) Clear cell sarcoma: the Roswell Park experience. J Surg Oncol 77:16–20PubMedCrossRef
16.
Lucas DR, Nascimento AG, Sim FH (1992) Clear cell sarcoma of soft tissues. Mayo Clinic experience with 35 cases. Am J Surg Pathol 16:1197–1204PubMedCrossRef
17.
Radstone DJ, Revell PA, Path MRC et al (1979) Clear cell sarcoma of tendons and aponeuroses treated with bleomycin and vincristine. Br J Radiol 52:238–241PubMedCrossRef
18.
Steger GG, Wrba F, Mader R et al (1991) Complete remission of metastasized clear cell sarcoma of tendons and aponeuroses. Eur J Cancer 27:254–256PubMedCrossRef
19.
Tomita K, Tsuchiya H (1989) Caffeine enhancement of the effect of anticancer agents on human sarcoma cells. Jpn J Cancer Res 80:83–88PubMedCrossRef
20.
Tomita K, Tsuchiya H (1989) Enhancement of cytocidal and antitumor effect of CDDP by caffeine in human osteosarcoma. Clin Ther 11:43–52PubMed
21.
Yasutake H, Tsuchiya H, Tomita K et al (1995) Inhibitory effect of caffeine on potentially lethal damage repair in CDDP-treated human osteosarcoma cells. Anticancer Res 15:831–838PubMed
22.
Tsuchiya H, Mori Y, Ueda Y et al (2000) Sensitization and caffeine potentiation of CDDP cytotoxicity resulting from introduction of wild-type p53 gene in human osteosarcoma. Anticancer Res 20:235–242PubMed
23.
Takeda A, Tsuchiya H, Tajino T et al (2005) An experimental study on the therapeutic effect of consecutive low-dose CDDP with caffeine in sarcoma-bearing mice. Anticancer Res 25:2777–2784PubMed
24.
Tsuchiya H, Yasutake H, Yokogawa A et al (1992) Effect of chemotherapy combined with caffeine for osteosarcoma. J Cancer Res Clin Oncol 118:567–569PubMedCrossRef
25.
Tsuchiya H, Yamamoto N, Asada N et al (2000) Caffeine-potentiated radiochemotherapy and function-saving surgery for high-grade soft tissue sarcoma. Anticancer Res 20:2137–2143PubMed
26.
Hayashi M, Tsuchiya H, Yamamoto N et al (2005) Caffeine-potentiated chemotherapy for metastatic carcinoma and lymphoma of bone and soft tissue. Anticancer Res 25:2399–2405PubMed
27.
Takeuchi A, Tsuchiya H, Yamamoto N et al (2007) Caffeine-potentiated chemotherapy for patients with high-grade soft tissue sarcoma: long-term clinical outcome. Anticancer Res 27:3489–3496PubMed
Metadata
Title
Caffeine-potentiated chemotherapy for clear cell sarcoma: a report of five cases
Authors
Michiaki Karita
Hiroyuki Tsuchiya
Norio Yamamoto
Toshiharu Shirai
Katsuhiro Hayashi
Hideji Nishida
Publication date
01-02-2013
Publisher
Springer Japan
Published in
International Journal of Clinical Oncology / Issue 1/2013
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-011-0337-9

Other articles of this Issue 1/2013

International Journal of Clinical Oncology 1/2013 Go to the issue

Original Article

Third-line sunitinib following sequential use of cytokine therapy and sorafenib in Japanese patients with metastatic renal cell carcinoma

Original Article

Evaluation of safety, pharmacokinetics, and efficacy of vorinostat, a histone deacetylase inhibitor, in the treatment of gastrointestinal (GI) cancer in a phase I clinical trial

Original Article

Randomized controlled study of natural interferon α as adjuvant treatment for stage II or III renal cell carcinoma

Original Article

Pharmacoethnicity of docetaxel-induced severe neutropenia: integrated analysis of published phase II and III trials

Original Article

Computed tomography fluoroscopy-guided radiofrequency ablation following intra-arterial iodized-oil injection for hepatocellular carcinomas invisible on ultrasonographic images

Original Article

Neoadjuvant and adjuvant chemotherapy with modified mesna, adriamycin, ifosfamide, and dacarbazine (MAID) regimen for adult high-grade non-small round cell soft tissue sarcomas
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits